Granting the wishes of anti-abortion groups, the Trump administration announced it will end fetal tissue research by government scientists; Insys Therapeutics has agreed to pay $225 million to settle federal investigations into allegations that the manufacturer paid kickbacks and used other illegal tactics to sell a powerful fentanyl spray; Medicaid enrollees who would potentially be subject to Medicaid work requirements are likely to face barriers to employment.
The Trump administration said Wednesday that they have discontinued all internal research that involves fetal tissue, putting an end to fetal tissue research by government scientists. The announcement was welcome news to anti-abortion activists, as fetal tissue is obtained through elective abortions. According to a statement from HHS, external fetal-tissue projects that receive government funding will continue, but new or renewed grant applications will require approval from an ethics advisory board. Scientists have spoken out against the announcement, saying that fetal tissue research has been essential to developing life-saving therapies.
Opioid manufacturer Insys Therapeutics has agreed to pay $225 million to settle federal investigations into allegations that the manufacturer paid kickbacks and used other illegal tactics to sell Susbys, a fentanyl spray meant for patients with cancer with severe pain, reported the Associated Press. The settlement comes a month after Insys founder John Kapoor and other former executives of the company were convicted of bribing doctors to prescribe the drug. As part of the agreement, the company will enter a 5-year deferred prosecution agreement with the Justice Department and its operating subsidiary will plead guilty to 5 counts of mail fraud.
Medicaid enrollees who would potentially be subject to Medicaid work requirements implemented by their state are more likely to face barriers to sustained employment compared with privately insured adults, according to a brief from the Urban Institute. Barriers include low education level, health problems, limited transportation and internet access, criminal history, and residence in high-unemployment or high-poverty neighborhoods. Less than 1 in 6 potentially affected Medicaid enrollees reported working at least 20 hours per week for nearly all weeks in the past year, compared with more than 3 in 5 privately insured adults.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More